Small Molecules

14 Oct 2020 Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's Lymphoma
14 Oct 2020 SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of SDN-037 for the Treatment of Inflammation and Pain Associated with Ocular Surgery
13 Oct 2020 Nuvation Bio Announces FDA Acceptance of Investigational New Drug (IND) Application for NUV-422 for Treatment of Patients with High-grade Gliomas
13 Oct 2020 Linnaeus Therapeutics Announces First Patient Dosed in Its Clinical Trial of LNS8801 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Cancer
13 Oct 2020 Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
13 Oct 2020 Phase 2b/3 trial shows efficacy of filgotinib for the induction and maintenance of remission in moderately and severely active ulcerative colitis
13 Oct 2020 Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH
13 Oct 2020 Basilea reports interim results from phase 1/2 study FIDES-02 exploring derazantinib in patients with advanced urothelial cancer
13 Oct 2020 Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs
12 Oct 2020 Priothera closes €30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML)
11 Oct 2020 Bristol Myers Squibb Presents Positive Late-Breaking Data from Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Adult Patients with Moderate to Severe Ulcerative Colitis
10 Oct 2020 Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100
10 Oct 2020 Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed with TP-1454 in Patients with Advanced Solid Tumors
10 Oct 2020 PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint
10 Oct 2020 Sobi announces topline phase 3 data of avatrombopag for the treatment of Chemotherapy-Induced Thrombocytopenia
09 Oct 2020 Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor
09 Oct 2020 Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor
09 Oct 2020 Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen
08 Oct 2020 Vincera Pharma, Inc Announces Exclusive License Agreement for Oncology Portfolio Including a Clinical-stage PTEFb/CDK9 Inhibitor and a Preclinical Bioconjugation Platform
08 Oct 2020 Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
08 Oct 2020 Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines
08 Oct 2020 Treatment With Islatravir and Doravirine Maintained Viral Suppression and No Viral Resistance was Identified
07 Oct 2020 Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
07 Oct 2020 AbFero Announces PK Study Results For SP-420 In Transfusional Iron Overload -- Proceeds With Phase 1-2 Trial Of Iron Chelator
06 Oct 2020 SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up